The elevated expression of haemoxygenase, which is an Nrf1/2 dependent gene, as a result of PB treatment in BRCA1 blocked BG1 ovarian cancer cell has also been reported earlier by our own group, confirming the activation of the antioxidant mechanism9. The gene discussed is NRF1; the disease is ovarian cancer.